Ascletis Pharma Inc.

Investors

2024

2023

2022

2021

2020

2019

2018

Annual Report 2019
2020-04-22
Voluntary Announcement - IND Approval of ASC09/Ritonavir Fixed-dose Combination
2020-04-13
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2020
2020-04-02
Voluntary Announcement - Data on NASH Candidate ASC40 to be Presented at EASL ILC 2020
2020-04-01
Grant of Share Options
2020-03-31
2019 Annual Results
2020-03-24
Notice of Board Meeting
2020-03-11
Announcement - Inside Information - Progress of the Small Sample Clinical Trial of Ganovo (Danoprevir) and Ritonavir Combination Therapy on Novel Coronavirus Pneumonia
2020-03-10
Monthly Return of Equity Issuer on Movements in Securities for the month ended 29 February 2020
2020-03-03
Announcement - Inside Information - Clinical Trial of Ganovo and Ritonavir Combination Therapy on Novel Coronavirus Pneumonia
2020-02-27

6

© 2018 Ascletis Pharma Inc. All Rights Reserved
浙公网安备 33010802003344号浙ICP备11050387号-1